<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126633</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000437858</org_study_id>
    <secondary_id>UCSF-04451</secondary_id>
    <secondary_id>GENENTECH-AVF2937s</secondary_id>
    <nct_id>NCT00126633</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Study of Fixed-Dose Rate Gemcitabine, Cisplatin, and Bevacizumab in Previously Untreated Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of tumor cells by blocking blood flow to the tumor. Giving gemcitabine and cisplatin&#xD;
      together with bevacizumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine and cisplatin together&#xD;
      with bevacizumab works in treating patients with metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine time to disease progression in patients with previously untreated metastatic&#xD;
           adenocarcinoma of the pancreas treated with gemcitabine, cisplatin, and bevacizumab.&#xD;
&#xD;
        -  Determine the safety and toxicity of this regimen in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the objective response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the efficacy of this regimen, in terms of the proportion of patients with ≥ a&#xD;
           50% decline in the CA19-9 biomarker, in these patients.&#xD;
&#xD;
        -  Determine the median survival of patients treated with this regimen.&#xD;
&#xD;
        -  Correlate serum markers of angiogenesis and circulating tumor micrometastases with&#xD;
           clinical outcome of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 100 minutes, cisplatin IV over 30-60 minutes, and&#xD;
      bevacizumab* IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up&#xD;
      to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may&#xD;
      receive additional study treatment at the discretion of the investigator.&#xD;
&#xD;
      NOTE: *Patients may continue to receive other components of therapy if bevacizumab is&#xD;
      discontinued due to toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 28 days and then monthly&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 12-18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as measured by NCI CTC version 2.0</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Micrometastases for predicting time to progression and overall survival</measure>
  </primary_outcome>
  <enrollment type="Actual">53</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  Must have documented extrapancreatic metastases&#xD;
&#xD;
                    -  Radiographically measurable disease is not required&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  No CNS or brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL (transfusion or epoetin alfa [Epogen®] support allowed)&#xD;
&#xD;
          -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  INR ≤ 1.5 (except for patients receiving full-dose warfarin)&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST or ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Urine protein:creatinine ratio ≤ 1&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction or stroke within the past 6 months&#xD;
&#xD;
          -  No uncontrolled hypertension (i.e., blood pressure &gt; 160/110 mm Hg despite&#xD;
             antihypertensive therapy)&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No unstable symptomatic arrhythmia requiring medication&#xD;
&#xD;
               -  Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal&#xD;
                  supraventricular tachycardia) are eligible&#xD;
&#xD;
          -  No peripheral vascular disease ≥ grade 2&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated nonmelanoma skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious systemic disease&#xD;
&#xD;
          -  No history of any other disease, metabolic dysfunction, physical examination finding,&#xD;
             or clinical laboratory finding that would preclude study treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 28 days since prior major surgery, or open biopsy&#xD;
&#xD;
          -  More than 7 days since prior fine needle aspirations or core biopsies&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior therapy, including systemic or investigational therapy, for locally advanced&#xD;
             or metastatic pancreatic cancer&#xD;
&#xD;
               -  Treatment given in the adjuvant setting (e.g., radiotherapy and/or chemotherapy,&#xD;
                  given either concurrently or systemically) is not considered prior therapy&#xD;
                  provided progressive disease occurred &gt; 6 months after completion of prior&#xD;
                  treatment&#xD;
&#xD;
          -  Concurrent continuation of therapeutic doses of warfarin or low-molecular weight&#xD;
             heparin allowed for pulmonary embolism, deep vein thrombosis, atrial fibrillation, or&#xD;
             other clinical indications provided patients has been on a stable dose for ≥ 28 days&#xD;
             with no further clotting or bleeding complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Ko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct;26(5):463-71. doi: 10.1007/s10637-008-9127-2. Epub 2008 Apr 1.</citation>
    <PMID>18379729</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

